BamSEC and AlphaSense Join Forces
Learn More

SignPath Pharma, Inc.

Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 15 pages Employment Agreement
12/34/56
EX-10.17
from 10-K 3 pages Amendment No. 1 to Employment Agreement
12/34/56
EX-10.16
from 10-K 2 pages Sponsored Research Agreement Amendment 1
12/34/56
EX-10.15
from 10-K 10 pages Sponsored Research Agreement
12/34/56
EX-10.12
from 10-K 22 pages SignPath Pharma Inc. Private Placement of Units Placement Agency Agreement
12/34/56
EX-10.11
from 10-K 16 pages Patent and Technology License Agreement
12/34/56
EX-10.9
from 10-K 24 pages Exclusive License Agreement
12/34/56
EX-10.7
from 10-K 2 pages Amendment III to the Agreement for the Manufacturing of a Liposomal Formulation
12/34/56
EX-10.6
from 10-K 2 pages Amendment II to the Agreement for the Manufacturing of a Liposomal Formulation
12/34/56
EX-10.12
from 10-K 21 pages SignPath Pharma Inc. Private Placement of Units Placement Agency Agreement
12/34/56
EX-10.1
from 10-K 12 pages Employment Agreement
12/34/56
EX-10.17
from 10-K 7 pages Material contract
12/34/56
EX-10.1
from 8-K 4 pages July 12, 2010 Jack Levine 16855 Ne 2nd Avenue North Miami Beach, Fl 33162 Re: Director Offer Letter
12/34/56
EX-10.16
from 10-K 5 pages Material contract
12/34/56
EX-10.15
from 10-K 1 page Material contract
12/34/56
EX-10.14
from S-1/A 1 page Material contract
12/34/56
EX-10.13
from S-1/A 4 pages Indemnification Agreement
12/34/56
EX-10.12
from S-1/A 25 pages SignPath Pharma, Inc. Private Placement of Units Placement Agency Agreement
12/34/56
EX-10.11
from S-1/A 12 pages Below Are Details of Our Current Understanding of the Requirements and Expectations of Safc, Based on Discussions to Date. These Sections Would Form the Basis of a Formal Technical Proposal Between Dr. Helson and Safc
12/34/56
EX-10.10
from S-1/A 9 pages Sponsored Research Agreement
12/34/56